Personal information

Other IDs

Loop profile: 746738
ResearcherID: I-3399-2012

Activities

Collapse all

Employment (5)

Hunter Medical Research Institute: NSW, NSW, AU

Employment
Source: Self-asserted source
Matthew D Dun

University of Newcastle Australia: Newcastle, AU

2023-03-30 to present | Professor Paediatric Heamatology/Oncology Research (Medical Biochemistry)
Employment
Source: Self-asserted source
Matthew D Dun

University of Newcastle: Callagahan, NSW, AU

2021-01-01 to 2023-03-30 | Associate Professor (Medical Biochemistry)
Employment
Source: Self-asserted source
Matthew D Dun

The University of Newcastle Hunter Medical Research Institute: Callaghan, NSW, AU

2018-01-01 to 2020-12-31 | Senior Lecturer (Medical Biochemistry)
Employment
Source: Self-asserted source
Matthew D Dun

University of Newcastle Australia: Newcastle, AU

2014 to 2016 | Lecturer (Medical Biochemistry)
Employment
Source: Self-asserted source
Matthew D Dun

Education and qualifications (3)

Hunter Medical Research Institute: NSW, NSW, AU

2009-01-26 to 2012-04-20 | PhD (Reproductive Sciences)
Education
Source: Self-asserted source
Matthew D Dun

University of Newcastle: Callaghan, NSW, AU

2008-02-06 to 2008-11-14 | Honours (SELS)
Education
Source: Self-asserted source
Matthew D Dun

University of Newcastle: Callaghan, NSW, AU

2004-02-26 to 2007-11-17 | Biotechnology (SELS)
Education
Source: Self-asserted source
Matthew D Dun

Professional activities (24)

Therapeutic Goods Administration: Canberra, NSW, AU

Executive - Therapeutic Advisory Committee DMG-ACT
Invited position
Source: Self-asserted source
Matthew D Dun

Society for Neuro Oncology: Houston, Texas, US

Associate Editor - Neuro-Oncology
Invited position
Source: Self-asserted source
Matthew D Dun

Mark Hughes Foundation Centre for Brain Cancer Research: Newcastle, NSW, AU

Leader Paediatric Stream
Invited position
Source: Self-asserted source
Matthew D Dun

Hunter Medical Research Institute: Newcastle, AU

Director Brain Cancer Research (Precision Medicine Research Program)
Invited position
Source: Self-asserted source
Matthew D Dun

Australian and New Zealand Children’s Haematology/Oncology Group: Clayton, AU

2021 to present
Membership
Source: Self-asserted source
Matthew D Dun

Society of Neuro Oncology (SNO): Houston, Texas, US

2020 to present
Membership
Source: Self-asserted source
Matthew D Dun

Frontiers in Oncology: Lausanne , CH

2019-05-01 to present | Editorial Board (Hematology)
Service
Source: Self-asserted source
Matthew D Dun

The Brain Foundation: Chatswood, NSW, AU

2019 to present
Membership
Source: Self-asserted source
Matthew D Dun

National Health and Medical Research Council: Canberra, ACT, AU

2019 to 2024-12-31 | Investigator Grants Reveiw Panel
Invited position
Source: Self-asserted source
Matthew D Dun

Australian Society for Medical Research: Sydney, AU

2024 | 2024 Australian Society for Medical Research Medalist
Distinction
Source: Self-asserted source
Matthew D Dun

Pediatric Neuro-Oncology Consortium: California, US

2023 | Basic Science Trailblazer
Distinction
Source: Self-asserted source
Matthew D Dun

International DIPG/DMG/Medulloblastoma Symposium: Tennessee, US

2023 | Innovator Award
Distinction
Source: Self-asserted source
Matthew D Dun

Hunter Medical Research Institute: Newcastle, AU

2023 | Director's Mid-Career Researcher of the Year
Distinction
Source: Self-asserted source
Matthew D Dun

Cure Starts Now Foundation: Cincinnati, US

2023 | Innovator of the Year (DIPG/DMG Collaborative)
Distinction
Source: Self-asserted source
Matthew D Dun

ChadTough Foundation: Saline, US

2023 | Spirit Award (Defeat DIPG)
Distinction
Source: Self-asserted source
Matthew D Dun

University of Newcastle Australia: Newcastle, AU

2022 | Mid-Career Researcher of the Year (College of Health, Medicine and Wellbeing)
Distinction
Source: Self-asserted source
Matthew D Dun

Society for Neuro Oncology: Houston, US

2022 | Top Ranking Abstract, Plenary Presentation (Annual Meeting 2022)
Distinction
Source: Self-asserted source
Matthew D Dun

Hunter Medical Research Institute: Newcastle, AU

2022 | Director's Mid-Career Researcher of the Year Finalist
Distinction
Source: Self-asserted source
Matthew D Dun

ChadTough Foundation: Saline, US

2022 | Big Hero Award (Defeat DIPG)
Distinction
Source: Self-asserted source
Matthew D Dun

University of Newcastle Australia: Newcastle, AU

2020 | Kellerman Award for Outstanding Contribution to Medical Biochemistry
Distinction
Source: Self-asserted source
Matthew D Dun

Hunter Children's Research Foundation: Newcastle, NSW, AU

2020 | Achievement in Paediatric Research
Distinction
Source: Self-asserted source
Matthew D Dun

Australian Institute of Policy and Science: Sydney, AU

2020 | Tall Poppy Award for Science
Distinction
Source: Self-asserted source
Matthew D Dun

Cancer Institute NSW: Sydney, AU

2019 | NSW Premier's Award for Outstanding Research Fellow
Distinction
Source: Self-asserted source
Matthew D Dun

Australian Society for Medical Research: Sydney, NSW, AU

2016 to 2018 | Director
Invited position
Source: Self-asserted source
Matthew D Dun

Funding (73)

UON Philanthropic Scholarship for Diffuse Midline Glioma Research

2025 to 2028 | Grant
University of Newcastle Australia (Newcastle, AU)
GRANT_NUMBER:

G2401561
Source: Self-asserted source
Matthew D Dun

Artificial intelligence for the advancement of diffuse midline glioma research

2024 to 2029 | Grant
Graham and Ann Burns (Callaghan, NSW, AU)
GRANT_NUMBER:

G2400968
Source: Self-asserted source
Matthew D Dun

Priming the blood-brain barrier to improve drug delivery and treatment outcomes in diffuse midline glioma

2024 to 2027 | Grant
Cancer Australia (Sydney, AU)
GRANT_NUMBER:

G2401060
Source: Self-asserted source
Matthew D Dun

Taming free radicals to silence the epigenome of kinase active paediatric cancers

2024 to 2027 | Grant
Cancer Australia (Sydney, AU)
GRANT_NUMBER:

G2300802
Source: Self-asserted source
Matthew D Dun

Targeting the metabolic dependencies of diffuse midline glioma

2024 to 2026 | Grant
Kids' Cancer Project (Alexandria, AU)
GRANT_NUMBER:

G2301313
Source: Self-asserted source
Matthew D Dun

Utilising a translational nanopharmaceutics approach to improving drug delivery in diffuse intrinsic pontine glioma

2024 to 2025 | Grant
Mark Hughes Foundation (NSW, NSW, AU)
GRANT_NUMBER:

G2301481
Source: Self-asserted source
Matthew D Dun

HMRI Award for Mid-Career Research 2023

2024 to 2024 | Award
Hunter Medical Research Institute (Newcastle, AU)
GRANT_NUMBER:

G2400154
Source: Self-asserted source
Matthew D Dun

Identification of a novel immuno-oncology target and extracellular matrix constituent in paediatric tumours of the central nervous system

2024 to 2024 | Grant
Kids' Cancer Project (Alexandria, AU)
GRANT_NUMBER:

G2400404
Source: Self-asserted source
Matthew D Dun

The Wish Lab

2024 to 2024 | Grant
RUN DIPG (Newcastle, NSW, AU)
GRANT_NUMBER:

G2401142
Source: Self-asserted source
Matthew D Dun

A chink in the armour of DMG tumours: Exploiting DMG-specific defence systems to improve response to treatment

2023 to 2026 | Grant
RUN DIPG (Newcastle, NSW, AU)
GRANT_NUMBER:

G2300913
Source: Self-asserted source
Matthew D Dun

ADDING DIMENSION TO DIFFUSE MIDLINE GLIOMA SUBTYPING – advanced tumour classification using a bioinformatics approach

2023 to 2026 | Grant
Kinghorn Foundation (VIC, VIC, AU)
GRANT_NUMBER:

G2300945
Source: Self-asserted source
Matthew D Dun

The RUN DIPG Warrior Jack Scholarship

2023 to 2026 | Grant
RUN DIPG (Newcastle, NSW, AU)
GRANT_NUMBER:

G2300606
Source: Self-asserted source
Matthew D Dun

Doubling Down: Enhancing the therapeutic benefit of investigational drugs for diffuse midline glioma

2023 to 2025 | Grant
The Blackjack Foundation (Brandy Hill, NSW, AU)
GRANT_NUMBER:

G2300289
Source: Self-asserted source
Matthew D Dun

Precision immunotherapeutic strategy for paediatric brain tumours

2023 to 2025 | Grant
Australian Lions Childhood Cancer Research Foundation (NSW, NSW, AU)
GRANT_NUMBER:

G2300290
Source: Self-asserted source
Matthew D Dun

DMG COMBATT 2.0: Diffuse Midline Glioma Combined Anti-Tumor Targeting 2.0

2023 to 2024 | Grant
Cure Starts Now Foundation (Cincinnati, US)
GRANT_NUMBER:

G2200705
Source: Self-asserted source
Matthew D Dun

Enhancing the recruitment of tumor infiltrating lymphocytes to improve responses to DMG therapies

2023 to 2024 | Grant
Cure Starts Now Foundation (Cincinnati, US)
GRANT_NUMBER:

G2200735
Source: Self-asserted source
Matthew D Dun

Establishment of a developmentally, genomically and immunologically relevant animal avatar of diffuse midline glioma

2023 to 2024 | Grant
Little Legs Foundation (Riverwood, NSW, AU)
GRANT_NUMBER:

G2301067
Source: Self-asserted source
Matthew D Dun

Evaluating promising anti-DMG therapies through enhanced collaboration

2023 to 2024 | Grant
RUN DIPG (Newcastle, NSW, AU)
GRANT_NUMBER:

G2300438
Source: Self-asserted source
Matthew D Dun

Establishment of a developmentally, genomically and immunologically relevant animal avatar of diffuse midline glioma

2023 to 2023 | Grant
Isabella and Marcus Foundation (VIC, VIC, AU)
GRANT_NUMBER:

G2301063
Source: Self-asserted source
Matthew D Dun

External collaboration_Domestic_Barreto

2023 to 2023 | Grant
University of Newcastle Australia (Newcastle, AU)
GRANT_NUMBER:

G2300418
Source: Self-asserted source
Matthew D Dun

Taming free radicals to increase response to standard-of-care treatments for children with high-risk leukaemias

2023 to 2023 | Grant
Hunter Medical Research Institute (Newcastle, AU)
GRANT_NUMBER:

G2300163
Source: Self-asserted source
Matthew D Dun

Targeting cholesterol biosynthesis for improved efficacy of hypomethylating agents in acute myeloid leukaemia

2023 to 2023 | Grant
Cure Cancer Australia (Sydney, AU)
GRANT_NUMBER:

G2200647
Source: Self-asserted source
Matthew D Dun

Targeting insulin signalling to overcome resistance to venetoclax in acute myeloid leukaemia (AML)

2023 to 2023 | Grant
Cure Cancer Australia (Sydney, AU)
GRANT_NUMBER:

G2200755
Source: Self-asserted source
Matthew D Dun

Targeting the untargetable - targeting the mutant genes, proteins and pathways responsible for paediatric high-grade gliomas, to improve treatment recommendations for patients

2023 to 2023 | Grant
Hunter Medical Research Institute (Newcastle, AU)
GRANT_NUMBER:

G2300692
Source: Self-asserted source
Matthew D Dun

The I-DIMENSIONS Project: Integrated DMG genomIc Methylomic EpigeNetic Spatial transcrIptomic prOteomic subtypiNg System

2023 to 2023 | Grant
Charlie Teo Foundation (NSW, NSW, AU)
GRANT_NUMBER:

G2300261
Source: Self-asserted source
Matthew D Dun

INTREPID - trINitarian TReatment tEmplate to imProve the survIval of DIPG patients

2022 to 2026 | Grant
Little Legs Foundation (Riverwood, NSW, AU)
GRANT_NUMBER:

G2201086
Source: Self-asserted source
Matthew D Dun

Pharmaco-phospho-proteo-genomics of paediatric high-grade glioma

2022 to 2025 | Grant
RUN DIPG (Newcastle, NSW, AU)
GRANT_NUMBER:

G2200066
Source: Self-asserted source
Matthew D Dun

in vitro and in vivo assessment of Aptabio-19 against acute high-risk leukaemias including patient-derived xenograft modelling.

2022 to 2024 | Grant
AptaBio Therapeutics Inc (Giheung, Kyonggi-do, KR)
GRANT_NUMBER:

G2200170
Source: Self-asserted source
Matthew D Dun

Pharmaco-phospho-proteo-genomics of paediatric high-grade glioma

2022 to 2024 | Grant
Kids' Cancer Project (Alexandria, AU)
GRANT_NUMBER:

G2101095
Source: Self-asserted source
Matthew D Dun

Developing analysis techniques to understand disease drivers and therapeutic vulnerability in diffuse intrinsic pontine glioma

2022 to 2022 | Grant
Schwab Charitable (San Francisco, California, US)
GRANT_NUMBER:

G2200293
Source: Self-asserted source
Matthew D Dun

Enhanced evaluation of disease drivers in high-risk paediatric cancers

2022 to 2022 | Grant
The Blackjack Foundation (Brandy Hill, NSW, AU)
GRANT_NUMBER:

G2200718
Source: Self-asserted source
Matthew D Dun

Progressing promising anti cancer strategies for the treatment of high-risk paediatric cancer

2022 to 2022 | Grant
Maitland Cancer Appeal Committee Incorporated (Maitland, NSW, AU)
GRANT_NUMBER:

G2200512
Source: Self-asserted source
Matthew D Dun

The Wish Lab

2022 to 2022 | Grant
RUN DIPG (Newcastle, NSW, AU)
GRANT_NUMBER:

G2200206
Source: Self-asserted source
Matthew D Dun

Understanding immune system involvement in diffuse midline glioma

2022 to 2022 | Grant
Liv like a Unicorn Foundation (New Jersey, US)
GRANT_NUMBER:

G2200389
Source: Self-asserted source
Matthew D Dun

Neoantigen immunopeptidomics for the development of immunotherapies for the treatment of diffuse intrinsic pontine glioma (DIPG)

2021 to 2024 | Grant
RUN DIPG (Newcastle, NSW, AU)
GRANT_NUMBER:

G2001148
Source: Self-asserted source
Matthew D Dun

Optimising novel central nervous system active drugs for the treatment of paediatric high-grade gliomas

2021 to 2024 | Grant
Strategic Group (Newcastle, NSW, AU)
GRANT_NUMBER:

G2100737
Source: Self-asserted source
Matthew D Dun

Unravelling genomic heterogeneity of diffuse intrinsic pontine glioma

2021 to 2023 | Grant
Hunter Medical Research Institute (Newcastle, AU)
GRANT_NUMBER:

G2100434
Source: Self-asserted source
Matthew D Dun

COMBATT DMG: Combined anti-tumour targeting of diffuse midline glioma

2021 to 2022 | Grant
Cure Starts Now Foundation (Cincinnati, US)
GRANT_NUMBER:

G2000780
Source: Self-asserted source
Matthew D Dun

In vivo evaluation of paxalisib for the treatment of diffuse midline glioma

2021 to 2022 | Grant
Kazia Therapeutics Limited (Sydney, NSW, AU)
GRANT_NUMBER:

G2101225
Source: Self-asserted source
Matthew D Dun

Cracking the Code: The launch of a genomic, epigenetic and proteomic pre-clinical platform to improve the treatment of paediatric leukemias

2021 to 2021 | Grant
Hunter Medical Research Institute (Newcastle, AU)
GRANT_NUMBER:

G2001337
Source: Self-asserted source
Matthew D Dun

Edie’s Kindness Research Donation

2021 to 2021 | Grant
Craig and Lois Jackson - Edie's Kindness Project (England, GB)
GRANT_NUMBER:

G2101278
Source: Self-asserted source
Matthew D Dun

Phosphoproteogenomic characterisation of diffuse intrinsic pontine glioma (DIPG)

2021 to 2021 | Grant
RUN DIPG (Newcastle, NSW, AU)
GRANT_NUMBER:

G2100084
Source: Self-asserted source
Matthew D Dun

Rapid advancement of central nervous system active therapies to clinical trial

2021 to 2021 | Grant
Pacific Pediatric Neuro-Oncology Consortium Foundation (San Rafael, California, US)
GRANT_NUMBER:

G2100894
Source: Self-asserted source
Matthew D Dun

Targeting NAPDH oxidase enzymes to improve the treatment of high-risk paediatric leukaemias

2021 to 2021 | Grant
Hunter Medical Research Institute (Newcastle, AU)
GRANT_NUMBER:

G2100141
Source: Self-asserted source
Matthew D Dun

The utility of specialised Blood Collection Tubes (STRECK-BCT) for the detection of CEA in colorectal cancer patients

2021 to 2021 | Grant
John Hunter Hospital Charitable Trust (Newcastle, AU)
GRANT_NUMBER:

G2001170
Source: Self-asserted source
Matthew D Dun

Mechanistic and translational studies to improve the outcomes of high-risk paediatric cancers

2020 to 2024 | Grant
National Health and Medical Research Council (Canberra, AU)
GRANT_NUMBER:

G1801489
Source: Self-asserted source
Matthew D Dun

Utilising male fertility as a biomarker of health to understand the biological effects of PFAS

2020 to 2023 | Grant
National Health and Medical Research Council (Canberra, AU)
GRANT_NUMBER:

G1900626
Source: Self-asserted source
Matthew D Dun

Harnessing the power from within: Neoantigen immunopeptidomics for the development of immunotherapies for the treatment of diffuse intrinsic pontine glioma (DIPG)

2020 to 2022 | Grant
Little Legs Foundation (Riverwood, NSW, AU)
GRANT_NUMBER:

G2000193
Source: Self-asserted source
Matthew D Dun

Unlocking oncogene addition to identify synergistic treatment targets for the treatment of diffuse intrinsic pontine glioma

2020 to 2022 | Grant
Michael Mosier Defeat DIPG Foundation (Maryland, US)
GRANT_NUMBER:

G1901112
Source: Self-asserted source
Matthew D Dun

Blueprint to a cure for diffuse intrinsic pontine glioma

2019 to 2020 | Grant
Tour de Cure (Sydney, AU)
GRANT_NUMBER:

G1901190
Source: Self-asserted source
Matthew D Dun

Moving safe and well-tolerated therapies from the bench to the clinic for the treatment of childhood brain cancer

2019 to 2020 | Grant
Hunter Medical Research Institute (Newcastle, AU)
GRANT_NUMBER:

G1901488
Source: Self-asserted source
Matthew D Dun

New horizons. Therapeutic applications for medicinal cannabis in the treatment of brain cancer

2019 to 2020 | Grant
Hunter Medical Research Institute (NSW, NSW, AU)
GRANT_NUMBER: G1900131
Source: Self-asserted source
Matthew D Dun

Targeting BCL6 for the treatment of relapsed FLT3 mutant acute myeloid leukaemia (AML)

2019 to 2020 | Grant
Hunter Medical Research Institute (Newcastle, AU)
GRANT_NUMBER:

G1901490
Source: Self-asserted source
Matthew D Dun

2019 NSW Premier's Awards for Outstanding Cancer Research — Outstanding Cancer Research Fellow: Dr Matthew Dun

2019 to 2019 | Award
Cancer Institute NSW (Sydney, AU)
GRANT_NUMBER:

G1901438
Source: Self-asserted source
Matthew D Dun

An integrated proteomics approach to identify novel targets for treatment of Acute Myeloid Leukaemia

2019 to 2019 | Contract
Takeda Pharmaceutical Company (Tokyo, JP)
GRANT_NUMBER:

G1801222
Source: Self-asserted source
Matthew D Dun

Characterisation of medicinal cannabis

2019 to 2019 | Award
Department of Industry, Innovation and Science (Canberra, AU)
GRANT_NUMBER:

G1801362
Source: Self-asserted source
Matthew D Dun

Kyratec PCR machine

2019 to 2019 | Grant
Hunter Medical Research Institute (NSW, NSW, AU)
GRANT_NUMBER:

G1900111
Source: Self-asserted source
Matthew D Dun

Preclinical research into the potential applications of GDC-0084 in diffuse intrinsic pontine glioma (DIPG)

2019 to 2019 | Grant
Kazia Therapeutics Limited (Sydney, NSW, AU)
GRANT_NUMBER:

G1801161
Source: Self-asserted source
Matthew D Dun

Investigation of disease markers in asymptomatic patients with colorectal carcinoma or colonic adenomas

2018 to 2022 | Grant
Streck Inc (La Vista, NE, US)
GRANT_NUMBER:

G1800707
Source: Self-asserted source
Matthew D Dun

Novel therapeutic targets and methods for detection of high grade brain cancers

2018 to 2021 | Grant
Hunter Medical Research Institute (NSW, NSW, AU)
GRANT_NUMBER:

G1800874
Source: Self-asserted source
Matthew D Dun

Elucidating the role of epididymosomes in the transfer of fertility-modulating proteins and regulatory classes of RNA to maturing spermatozoa

2018 to 2020 | Grant
National Health and Medical Research Council (ACT, ACT, AU)
GRANT_NUMBER:

G1700434
Source: Self-asserted source
Matthew D Dun

Non-invasive detection of DIPG specific DNA and protein using sequential blood collections

2018 to 2020 | Grant
Hunter Medical Research Institute (NSW, NSW, AU)
GRANT_NUMBER:

G1801235
Source: Self-asserted source
Matthew D Dun

Preclinical evaluation of novel therapies for the treatment of diffuse intrinsic pontine glioma

2018 to 2020 | Award
McDonald Jones Charitable Foundation (Newcastle, NSW, AU)
Source: Self-asserted source
Matthew D Dun

Proteomic architecture of diffuse pontine intrinsic glioma

2018 to 2020 | Award
McDonald Jones Charitable Foundation (Newcastle, NSW, AU)
GRANT_NUMBER:

G1801130
Source: Self-asserted source
Matthew D Dun

Building international collaborations for DIPG research

2018 to 2018 | Award
Hunter Medical Research Institute (NSW, NSW, AU)
GRANT_NUMBER:

G1801371
Source: Self-asserted source
Matthew D Dun

Capillary Flow Two Dimensional High Pressure Liquid Chromatography (HPLC) system

2018 to 2018 | Grant
National Health and Medical Research Council (ACT, ACT, AU)
GRANT_NUMBER:

G1800470
Source: Self-asserted source
Matthew D Dun

Enhancing the efficacy of new inhibitors targeting the PI3K–AKT–mTOR signalling axis for the treatment of high-grade diffuse intrinsic pontine gliomas (DIPG)

2018 to 2018 | Grant
Hunter Medical Research Institute (NSW, NSW, AU)
GRANT_NUMBER:

G1801386
Source: Self-asserted source
Matthew D Dun

Jennie Thomas Medical Research Travel Grant - Nikita Panicker

2018 to 2018 | Grant
Hunter Medical Research Institute (Newcastle, AU)
GRANT_NUMBER:

G1800024
Source: Self-asserted source
Matthew D Dun

Preclinical testing of new treatments for DIPG

2018 to 2018 | Grant
Hunter Medical Research Institute (NSW, NSW, AU)
GRANT_NUMBER:

G1801241
Source: Self-asserted source
Matthew D Dun

Proteomic Profiling of Chemoresistant Acute Lymphoblastic Leukemia-Derived Exosomes

2018 to 2018 | Grant
Hunter Medical Research Institute (NSW, NSW, AU)
GRANT_NUMBER:

G1801240
Source: Self-asserted source
Matthew D Dun

Targeting DNA repair for the improved treatment of blood cancers

2018 to 2018 | Grant
Hunter Medical Research Institute (NSW, NSW, AU)
GRANT_NUMBER:

G1800611
Source: Self-asserted source
Matthew D Dun

Targeting oncogenic signalling in DIPG using drugs that cross the blood brain barrier.

2018 to 2018 | Award
Australian Communties Foundation (Melbourne, Victoria, AU)
GRANT_NUMBER:

G1800977
Source: Self-asserted source
Matthew D Dun

Targeting Reactive Oxygen Species Generation as a Novel Treatment Target in Acute Myeloid Leukaemia - RA support

2018 to 2018 | Grant
Hunter Medical Research Institute (NSW, NSW, AU)
GRANT_NUMBER:

G1800399
Source: Self-asserted source
Matthew D Dun

Works (50 of 97)

Items per page:
Page 1 of 2

EZHIP’s role in diffuse midline glioma: echoes of oncohistones?

Trends in Cancer
2024-12 | Journal article
DOI: 10.1016/j.trecan.2024.09.002
Contributors: Afraah Cassim; Matthew D. Dun; David Gallego-Ortega; Fatima Valdes-Mora
Source: check_circle
Crossref

Pharmaco‐phosphoproteomic analysis of cancer‐associated KIT mutations D816V and V560G

PROTEOMICS
2024-05 | Journal article
DOI: 10.1002/pmic.202300309
Contributors: Heather C. Murray; Kasey Miller; Matthew D. Dun; Nicole M. Verrills
Source: check_circle
Crossref

A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered

Neuro-Oncology
2024-05-03 | Journal article
DOI: 10.1093/neuonc/noad144
Contributors: Evangeline R Jackson; Mika L Persson; Cameron J Fish; Izac J Findlay; Sabine Mueller; Javad Nazarian; Esther Hulleman; Jasper van der Lugt; Ryan J Duchatel; Matthew D Dun
Source: check_circle
Crossref

Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon

Neuro-Oncology
2024-05-03 | Journal article
DOI: 10.1093/neuonc/noad245
Contributors: Matthew D Dun; Yazmin Odia; Isabel Arrillaga-Romany
Source: check_circle
Crossref

CAR T cell therapies for diffuse midline glioma

Trends in Cancer
2023-10 | Journal article
DOI: 10.1016/j.trecan.2023.07.007
Contributors: Bryce C. Thomas; Dilana E. Staudt; Alicia M. Douglas; Michelle Monje; Nicholas A. Vitanza; Matthew D. Dun
Source: check_circle
Crossref

Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia

Molecular & Cellular Proteomics
2023-03 | Journal article
DOI: 10.1016/j.mcpro.2023.100503
Contributors: Heather C. Murray; Kasey Miller; Joshua S. Brzozowski; Richard G.S. Kahl; Nathan D. Smith; Sean J. Humphrey; Matthew D. Dun; Nicole M. Verrills
Source: check_circle
Crossref

Global profiling of the proteomic changes associated with the post-testicular maturation of mouse spermatozoa

Cell Reports
2022-11 | Journal article
DOI: 10.1016/j.celrep.2022.111655
Contributors: David A. Skerrett-Byrne; Amanda L. Anderson; Elizabeth G. Bromfield; Ilana R. Bernstein; Jess E. Mulhall; John E. Schjenken; Matthew D. Dun; Sean J. Humphrey; Brett Nixon
Source: check_circle
Crossref

The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies

Neuro-Oncology
2022-09-01 | Journal article
DOI: 10.1093/neuonc/noac117
Contributors: Mika L Persson; Alicia M Douglas; Frank Alvaro; Pouya Faridi; Martin R Larsen; Marta M Alonso; Nicholas A Vitanza; Matthew D Dun
Source: check_circle
Crossref

Proteome and secretome analysis of pancreatic cancer cells

PROTEOMICS
2022-07 | Journal article
DOI: 10.1002/pmic.202100320
Contributors: Xiang Li; Hui Liu; Matthew D. Dun; Sam Faulkner; Xiaoming Liu; Chen Chen Jiang; Hubert Hondermarck
Source: check_circle
Crossref

Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies

Oncogene
2022-01-21 | Journal article
DOI: 10.1038/s41388-021-02102-y
Contributors: Izac J. Findlay; Geoffry N. De Iuliis; Ryan J. Duchatel; Evangeline R. Jackson; Nicholas A. Vitanza; Jason E. Cain; Sebastian M. Waszak; Matthew D. Dun
Source: check_circle
Crossref

Dynamic Landscape of Extracellular Vesicle-Associated Proteins Is Related to Treatment Response of Patients with Metastatic Breast Cancer

Membranes
2021-11-16 | Journal article
DOI: 10.3390/membranes11110880
Contributors: Olivia Ruhen; Xinyu Qu; M. Fairuz B. Jamaluddin; Carlos Salomon; Aesha Gandhi; Michael Millward; Brett Nixon; Matthew D. Dun; Katie Meehan
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Acrylamide modulates the mouse epididymal proteome to drive alterations in the sperm small non-coding RNA profile and dysregulate embryo development

Cell Reports
2021-10 | Journal article
DOI: 10.1016/j.celrep.2021.109787
Contributors: Natalie A. Trigg; David A. Skerrett-Byrne; Miguel J. Xavier; Wei Zhou; Amanda L. Anderson; Simone J. Stanger; Aimee L. Katen; Geoffry N. De Iuliis; Matthew D. Dun; Shaun D. Roman et al.
Source: check_circle
Crossref

Proteomic analysis of koala (phascolarctos cinereus) spermatozoa and prostatic bodies

PROTEOMICS
2021-10 | Journal article
DOI: 10.1002/pmic.202100067
Contributors: David A. Skerrett‐Byrne; Amanda L. Anderson; Lyndal Hulse; Caillin Wass; Matthew D. Dun; Elizabeth G. Bromfield; Geoffry N. De Iuliis; Michael Pyne; Vere Nicolson; Stephen D. Johnston et al.
Source: check_circle
Crossref

Reactive Oxygen Species in Acute Lymphoblastic Leukaemia: Reducing Radicals to Refine Responses

Antioxidants
2021-10-14 | Journal article
DOI: 10.3390/antiox10101616
Contributors: Abdul Mannan; Zacary P. Germon; Janis Chamberlain; Jonathan R. Sillar; Brett Nixon; Matthew D. Dun
Source: check_circle
Crossref
grade
Preferred source (of 3)‎

A novel role for milk fat globule‐EGF factor 8 protein (MFGE8) in the mediation of mouse sperm–extracellular vesicle interactions

PROTEOMICS
2021-07 | Journal article
DOI: 10.1002/pmic.202000079
Contributors: Natalie A. Trigg; Simone J. Stanger; Wei Zhou; David A. Skerrett‐Byrne; Petra Sipilä; Matthew D. Dun; Andrew L. Eamens; Geoffry N. De Iuliis; Elizabeth G. Bromfield; Shaun D. Roman et al.
Source: check_circle
Crossref

SINEultaneous profiling of epigenetic heterogeneity and transcriptome in single cells

2021-03-25 | Preprint
DOI: 10.1101/2021.03.25.436351
Contributors: Kooper V Hunt; Sean M Burnard; Ellise A Roper; Danielle R Bond; Matthew D Dun; Nicole M Verrills; Anoop K Enjeti; Heather J Lee
Source: check_circle
Crossref

Shwachman–Bodian–Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia

Leukemia
2020-12-08 | Journal article
DOI: 10.1038/s41375-020-0814-0
Contributors: Matthew D. Dun; Abdul Mannan; Callum J. Rigby; Stephen Butler; Hamish D. Toop; Dominik Beck; Patrick Connerty; Jonathan Sillar; Richard G. S. Kahl; Ryan J. Duchatel et al.
Source: check_circle
Crossref

Cold Shock Domain Containing E1 (CSDE1) Protein is Overexpressed and Can be Targeted to Inhibit Invasiveness in Pancreatic Cancer Cells

PROTEOMICS
2020-05 | Journal article
DOI: 10.1002/pmic.201900331
Contributors: Hui Liu; Xiang Li; Matthew D. Dun; Sam Faulkner; Chen Chen Jiang; Hubert Hondermarck
Source: check_circle
Crossref

Can Hemp Help? Low-THC Cannabis and Non-THC Cannabinoids for the Treatment of Cancer

Cancers
2020-04-23 | Journal article
DOI: 10.3390/cancers12041033
Contributors: Farjana Afrin; Mengna Chi; Andrew L. Eamens; Ryan J. Duchatel; Alicia M. Douglas; Jennifer Schneider; Craig Gedye; Ameha S. Woldu; Matthew D. Dun
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Signal Transduction in Diffuse Intrinsic Pontine Glioma

PROTEOMICS
2019-11 | Journal article
DOI: 10.1002/pmic.201800479
Contributors: Ryan J. Duchatel; Evangeline R. Jackson; Frank Alvaro; Brett Nixon; Hubert Hondermarck; Matthew D. Dun
Source: check_circle
Crossref

The Role of Reactive Oxygen Species in Acute Myeloid Leukaemia

International Journal of Molecular Sciences
2019-11-28 | Journal article
DOI: 10.3390/ijms20236003
Contributors: Jonathan R. Sillar; Zacary P. Germon; Geoffry N. De Iuliis; Matthew D. Dun
Source: check_circle
Crossref

Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review

Journal of Surgical Research
2019-04 | Journal article
DOI: 10.1016/j.jss.2018.11.029
Contributors: Joel Petit; Georgia Carroll; Tiffany Gould; Peter Pockney; Matthew Dun; Rodney J. Scott
Source: check_circle
Crossref

Modification of Crocodile Spermatozoa Refutes the Tenet That Post-testicular Sperm Maturation Is Restricted To Mammals*

Molecular & Cellular Proteomics
2019-03-15 | Journal article
DOI: 10.1074/mcp.RA118.000904
Contributors: Brett Nixon; Stephen D. Johnston; David A. Skerrett-Byrne; Amanda L. Anderson; Simone J. Stanger; Elizabeth G. Bromfield; Jacinta H. Martin; Philip M. Hansbro; Matthew D. Dun
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Analysis of Epididymal Protein Synthesis and Secretion

Jove-Journal of Visualized Experiments
2018 | Journal article
DOI: 10.3791/58308
WOSUID:

WOS:000444913100148
Contributors: Zhou, Wei; Sipila, Petra; De Iuliis, Geoffry N.; Dun, Matthew D.; Nixon, Brett
Source: Self-asserted source
Matthew D Dun via ResearcherID

Characteristics of the Epididymal Luminal Environment Responsible for Sperm Maturation and Storage.

Frontiers in endocrinology
2018 | Journal article
DOI: 10.3389/fendo.2018.00059
PMID: 29541061
PMC: PMC5835514
Contributors: Zhou W; De Iuliis GN; Dun MD; Nixon B
Source: Self-asserted source
Matthew D Dun via Europe PubMed Central
grade
Preferred source (of 2)‎

Combinatorial Targeting of the c-KIT Receptor Tyrosine Kinase in Acute Myeloid Leukemia

Asia-Pacific Journal of Clinical Oncology
2018 | Journal article
WOSUID:

WOS:000446654600012
Contributors: Murray, Heather; Enjeti, Anoop K.; Kahl, Richard; Flanagan, Hayley; Verrills, Nikki; Dun, Matthew
Source: Self-asserted source
Matthew D Dun via ResearcherID

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.

Leukemia
2018 | Journal article
DOI: 10.1038/s41375-018-0241-7
WOSUID:

MEDLINE:30232463
Contributors: Degryse, S; de Bock, C E; Demeyer, S; Govaerts, I; Bornschein, S; Verbeke, D; Jacobs, K; Binos, S; Skerrett-Byrne, D A; Murray, H C et al.
Source: Self-asserted source
Matthew D Dun via ResearcherID

Development of Novel Model Systems for the Study of Resistance to Targeted Therapies in Acute Myeloid Leukemia

Asia-Pacific Journal of Clinical Oncology
2018 | Journal article
WOSUID:

WOS:000446654600027
Contributors: Staudt, Dilana; Duchatel, Ryan; Kahl, Richard; Murray, Heather; Scott, Rodney; Verrills, Nikki; Dun, Matthew
Source: Self-asserted source
Matthew D Dun via ResearcherID

Intracellular Oxidative Stress Modulates FLT3 Regulatory Proteins Contributing to Oncogenic Signaling in Acute Myeloid Leukemia

Asia-Pacific Journal of Clinical Oncology
2018 | Journal article
WOSUID:

WOS:000446654600035
Contributors: Germon, Zacary; Sillar, Jonathan; Murray, Heather; Duchatel, Ryan; Al-mazi, Juhura; Verrills, Nikki; Dun, Matthew
Source: Self-asserted source
Matthew D Dun via ResearcherID

Investigating ACVR1 and PI3K as Novel Therapeutic Targets in H3.1 K27M+Diffuse Intrinsic Pontine Glioma

Asia-Pacific Journal of Clinical Oncology
2018 | Journal article
WOSUID:

WOS:000446654600019
Contributors: Duchatel, Ryan; Jackson, Evangeline; Verrills, Nikki; Cain, Jason; Monje, Michelle; Alvaro, Frank; Dun, Matt
Source: Self-asserted source
Matthew D Dun via ResearcherID

Loss of Protein Phosphatase 2A Regulatory Subunit B55 alpha Enhances Tumor Progression and Tamoxifen Resistance in Luminal Breast Cancer

Asia-Pacific Journal of Clinical Oncology
2018 | Journal article
WOSUID:

WOS:000446654600024
Contributors: Mannan, Abdul; Roselli, Severine; Kahl, Richard G. S.; Skelding, Kathryn; Dun, Matthew; Verrills, Nikki
Source: Self-asserted source
Matthew D Dun via ResearcherID

Molecular Characterization of Treatment Resistance in FLT3 Mutant Pediatric Acute Myeloid Leukemia

Asia-Pacific Journal of Clinical Oncology
2018 | Journal article
WOSUID:

WOS:000446654600032
Contributors: Mclachlan, Tabitha; Murray, Heather; Skerrett-Byrne, David; Dubois, Oceane; Withers, Kaitlin; Verrills, Nikki; Dun, Matthew
Source: Self-asserted source
Matthew D Dun via ResearcherID

Proteomic profiling of mouse epididymosomes reveals their contributions to post-testicular sperm maturation.

Molecular & cellular proteomics : MCP
2018 | Journal article
DOI: 10.1074/mcp.RA118.000946
WOSUID:

MEDLINE:30213844
Contributors: Nixon, Brett; De Iuliis, Geoffry N; Hart, Hanah M; Zhou, Wei; Mathe, Andrea; Bernstein, Ilana; Anderson, Amanda L; Stanger, Simone J; Skerrett-Byrne, David A; Jamaluddin, M Fairuz B et al.
Source: Self-asserted source
Matthew D Dun via ResearcherID

Qualitative and Quantitative Detection of PrPSc Based on the Controlled Release Property of Magnetic Microspheres Using Surface Plasmon Resonance (SPR)

Nanomaterials
2018 | Journal article
DOI: 10.3390/nano8020107
WOSUID:

WOS:000427534600054
Contributors: Lou, Zhichao; Han, He; Mao, Dun; Jiang, Yibin; Song, Jianyue
Source: Self-asserted source
Matthew D Dun via ResearcherID

Quantitative Proteomics for the Early Detection of Colorectal Cancer

Asia-Pacific Journal of Clinical Oncology
2018 | Journal article
WOSUID:

WOS:000446654600036
Contributors: Gould, Tiffany; Jamaluddin, Muhammad F. B.; Pockney, Peter; Dun, Matthew
Source: Self-asserted source
Matthew D Dun via ResearcherID

Translating Fundamental Biology into a New Treatment for Therapy-Resistant Breast Cancer: Bench to Bedside and (almost) Back Again!

Asia-Pacific Journal of Clinical Oncology
2018 | Journal article
WOSUID:

WOS:000446654600007
Contributors: Verrills, Nikki; Mannan, Abdul; Panicker, Nikita; Chen, Yanfang; Coutman, Melody; Murray, Heather; Watt, Lauren; Kahl, Richard; Dun, Matthew; Roselli, Severine
Source: Self-asserted source
Matthew D Dun via ResearcherID

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance

International Journal of Molecular Sciences
2018-10 | Journal article | Author
DOI: 10.3390/ijms19103198
Contributors: Dilana Staudt; Heather C. Murray; Tabitha Mclachlan; Frank Alvaro; Anoop K. Enjeti; Nicole M. Verrills; Matthew D Dun
Source: check_circle
Multidisciplinary Digital Publishing Institute
grade
Preferred source (of 3)‎

Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: the Path to Least Resistance

2018-09-21 | Other
DOI: 10.20944/preprints201809.0435.v1
Contributors: Dilana Staudt; Heather Murray; Frank Alvaro; Anoop Enjeti; Nicole Verrills; Matthew D. Dun
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Extracellular vesicles with altered tetraspanin CD9 and CD151 levels confer increased prostate cell motility and invasion

Scientific Reports
2018-06-11 | Journal article
DOI: 10.1038/s41598-018-27180-z
Contributors: Joshua S. Brzozowski; Danielle R. Bond; Helen Jankowski; Belinda J. Goldie; Rachel Burchell; Crystal Naudin; Nathan D. Smith; Christopher J. Scarlett; Martin R. Larsen; Matthew D. Dun et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Cell-Free DNA Blood Collection Tubes Are Appropriate for Clinical Proteomics: A Demonstration in Colorectal Cancer.

Proteomics. Clinical applications
2018-05 | Journal article
DOI: 10.1002/prca.201700121
PMID: 29476593
PMC: PMC5947838
Contributors: Almazi JG; Pockney P; Gedye C; Smith ND; Hondermarck H; Verrills NM; Dun MD
Source: Self-asserted source
Matthew D Dun via Europe PubMed Central
grade
Preferred source (of 2)‎

Mouse quiescin sulfhydryl oxidases exhibit distinct epididymal luminal distribution with Segment-Specific sperm surface associations.

Biology of reproduction
2018-05 | Journal article
DOI: 10.1093/biolre/ioy125
PMID: 29800099
Contributors: Wang TE; Li SH; Minabe S; Anderson AL; Dun MD; Maeda KI; Matsuda F; Chang HW; Nixon B; Tsai PJ
Source: Self-asserted source
Matthew D Dun via Europe PubMed Central
grade
Preferred source (of 3)‎

Neuroproteins in cancer: assumed bystanders become culprits.

Proteomics
2018-05 | Journal article
DOI: 10.1002/pmic.201800049
PMID: 29745056
Contributors: Li X; Dun MD; Faulkner S; Hondermarck H
Source: Self-asserted source
Matthew D Dun via Europe PubMed Central
grade
Preferred source (of 3)‎

Pharmacological inhibition of arachidonate 15-lipoxygenase (ALOX15) protects human spermatozoa against oxidative stress.

Biology of reproduction
2018-03 | Journal article
DOI: 10.1093/biolre/ioy058
PMID: 29546268
Contributors: Walters JLH; De Iuliis GN; Dun MD; Aitken RJ; McLaughlin EA; Nixon B; Bromfield EG
Source: Self-asserted source
Matthew D Dun via Europe PubMed Central
grade
Preferred source (of 2)‎

Functional role of the tumor suppressor protein phosphatase, PP2A-B55 alpha, in breast cancer

Cancer Research
2017 | Journal article
DOI: 10.1158/1538-7445.AM2017-2375
WOSUID:

WOS:000442496705228
Contributors: Panicker, Nikita; Mannan, Abdul; Watt, Lauren F.; Copeland, Ben; Dun, Matt D.; King, Simon; Clarke, Megan; Skelding, Kathryn; Roselli, Severine; Verrills, Nicole M.
Source: Self-asserted source
Matthew D Dun via ResearcherID

Novel PP2A Inhibitory Protein in C-KIT Mutant Myeloid Progenitor Cells

Asia-Pacific Journal of Clinical Oncology
2017 | Journal article
WOSUID:

WOS:000413952600003
Contributors: Rigby, C.; Toop, H.; Al Mazi, J.; Morris, J.; Enjeti, A.; Verrills, N.; Dun, M.
Source: Self-asserted source
Matthew D Dun via ResearcherID

Reduced Expression of the Protein Phosphatase 2A Regulatory Subunit B55 alpha in Luminal Breast Cancer: Effect on Tumor Progression and Antihormonal Therapy

Asia-Pacific Journal of Clinical Oncology
2017 | Journal article
WOSUID:

WOS:000413952600011
Contributors: Mannan, A.; Panicker, N.; Kahl, R.; Skelding, K.; Dun, M.; Verrills, N.
Source: Self-asserted source
Matthew D Dun via ResearcherID

Targeting Error-Prone DNA Double-Strand Break Repair in Acute Myeloid Leukaemia (AML)

Asia-Pacific Journal of Clinical Oncology
2017 | Journal article
WOSUID:

WOS:000413952600019
Contributors: Murray, H.; Kahl, R.; Smith, N.; Enjeti, A.; Larsen, M.; Verrills, N.; Dun, M.
Source: Self-asserted source
Matthew D Dun via ResearcherID

To Quantitate DNA Damage Repair Pathways in Human Cancers VIA Establishment of a Sensitive and Quantitative Mass Spectrometry-Based Assay

Asia-Pacific Journal of Clinical Oncology
2017 | Journal article
WOSUID:

WOS:000413952600013
Contributors: Chen, Y.; Al Mazi, J.; Panicker, N.; Mannan, A.; Murray, H.; Dun, M.; Verrills, N.
Source: Self-asserted source
Matthew D Dun via ResearcherID

Proteomic profiling of human uterine fibroids reveals upregulation of the extracellular matrix protein periostin.

Endocrinology
2017-12 | Journal article
DOI: 10.1210/en.2017-03018
PMID: 29244110
Contributors: Jamaluddin MFB; Ko YA; Kumar M; Brown Y; Bajwa P; Nagendra PB; Skerrett-Byrne D; Hondermarck H; Baker MA; Dun MD et al.
Source: Self-asserted source
Matthew D Dun via Europe PubMed Central
grade
Preferred source (of 2)‎

Characterization of the early molecular changes in the glomeruli of Cd151 -/- mice highlights induction of mindin and MMP-10.

Scientific reports
2017-11 | Journal article
DOI: 10.1038/s41598-017-15993-3
PMID: 29167507
PMC: PMC5700190
Contributors: Naudin C; Smith B; Bond DR; Dun MD; Scott RJ; Ashman LK; Weidenhofer J; Roselli S
Source: Self-asserted source
Matthew D Dun via Europe PubMed Central
grade
Preferred source (of 2)‎
Items per page:
Page 1 of 2

Peer review (53 reviews for 18 publications/grants)

Review activity for Asia-Pacific journal of clinical oncology. (3)
Review activity for BMC genomics (1)
Review activity for Cancers. (5)
Review activity for Cell death and disease. (1)
Review activity for Children. (1)
Review activity for Clinical & experimental metastasis. (1)
Review activity for International journal of molecular sciences. (2)
Review activity for iScience. (1)
Review activity for Journal of clinical oncology : (3)
Review activity for Journal of experimental & clinical cancer research. (2)
Review activity for Leukemia (1)
Review activity for Nature (1)
Review activity for Nature communications (3)
Review activity for Neoplasia. (2)
Review activity for Neuro-oncology. (12)
Review activity for Neuro-oncology. (12)
Review activity for Reproduction, fertility, and development. (1)
Review activity for Trends in cancer. (1)
How many people are using ORCID?